company background image
300584 logo

Nanjing Hicin Pharmaceutical SZSE:300584 Stock Report

Last Price

CN¥20.05

Market Cap

CN¥2.4b

7D

-14.8%

1Y

-1.7%

Updated

23 Aug, 2024

Data

Company Financials

Nanjing Hicin Pharmaceutical Co., Ltd.

SZSE:300584 Stock Report

Market Cap: CN¥2.4b

300584 Stock Overview

Engages in the research, development, manufacture, marketing, and sale of pharmaceuticals, pharmaceutical preparations, and synthetic chemicals in China.

300584 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health3/6
Dividends0/6

Nanjing Hicin Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nanjing Hicin Pharmaceutical
Historical stock prices
Current Share PriceCN¥20.05
52 Week HighCN¥33.00
52 Week LowCN¥12.68
Beta0.11
11 Month Change31.05%
3 Month Change17.39%
1 Year Change-1.72%
33 Year Change17.32%
5 Year Change-37.73%
Change since IPO87.97%

Recent News & Updates

There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

Aug 15
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

May 01
We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

Recent updates

There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

Aug 15
There's Reason For Concern Over Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Massive 28% Price Jump

We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

May 01
We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues

Mar 08
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 29% Price Boost Is Out Of Tune With Revenues

Shareholder Returns

300584CN PharmaceuticalsCN Market
7D-14.8%-4.0%-2.3%
1Y-1.7%-10.0%-17.3%

Return vs Industry: 300584 exceeded the CN Pharmaceuticals industry which returned -10.1% over the past year.

Return vs Market: 300584 exceeded the CN Market which returned -18.4% over the past year.

Price Volatility

Is 300584's price volatile compared to industry and market?
300584 volatility
300584 Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement5.5%
10% most volatile stocks in CN Market8.9%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 300584's share price has been volatile over the past 3 months.

Volatility Over Time: 300584's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2003553Yuping Caowww.hicin.cn/page1/index1

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals, pharmaceutical preparations, and synthetic chemicals in China. It offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. The company also provides technical transferring services.

Nanjing Hicin Pharmaceutical Co., Ltd. Fundamentals Summary

How do Nanjing Hicin Pharmaceutical's earnings and revenue compare to its market cap?
300584 fundamental statistics
Market capCN¥2.41b
Earnings (TTM)CN¥37.46m
Revenue (TTM)CN¥505.19m

64.2x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300584 income statement (TTM)
RevenueCN¥505.19m
Cost of RevenueCN¥99.15m
Gross ProfitCN¥406.04m
Other ExpensesCN¥368.58m
EarningsCN¥37.46m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.31
Gross Margin80.37%
Net Profit Margin7.41%
Debt/Equity Ratio27.0%

How did 300584 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

16%

Payout Ratio